Spray Drying of Amifostine
Amifostine is a cytoprotective agent used to reduce side effects of cancer therapies. Spray drying enables the production of stable, patient-friendly powders with optimized particle properties and bioavailability. It supports oral formulations with controlled release for improved therapeutic outcomes. Application Note No. 427 provides starting parameters, formulations, and results, including Amifostine/PLGA concentrations and solvent systems.
Concentración de muestra de Amifostina/PLGA (0,4:1,0 y 1:1), Amifostina (400 mg/1 ml o 1000 mg/2 ml) en agua desionizada y emulsionada en 50 ml de diclorometano que contiene 1 g de PLGA. Disolvente de Amifostina en agua, PLGA en portador de DCM, Filmógeno Poli (ácido DL-láctico-glicólico) PLGA 50:50 (RG 502; viscosidad intrínseca de 0,2 dL/g), Fosfatidilcolina (surfactante).
